BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8728920)

  • 1. [A quantitative study on nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma].
    Liu C; Zhao Y; Sun X
    Zhonghua Fu Chan Ke Za Zhi; 1995 Dec; 30(12):738-40. PubMed ID: 8728920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic significance of cellular DNA content and AgNOR count in ovarian cystadenoma].
    Lu XL; Yi WM; Wang LF
    Ai Zheng; 2003 Jan; 22(1):62-5. PubMed ID: 12561439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relation between DNA content in ovarian cystadenoma and its pathohistology].
    Sun ZC
    Zhonghua Fu Chan Ke Za Zhi; 1993 Dec; 28(12):731-3, 760-1. PubMed ID: 8137645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of decreased mitochondrial DNA content with ovarian cancer progression.
    Wang Y; Liu VW; Xue WC; Cheung AN; Ngan HY
    Br J Cancer; 2006 Oct; 95(8):1087-91. PubMed ID: 17047655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA content and morphological parameters in synovial sarcoma and synovioma.
    Lu C; Xia J; Yang M
    Chin Med J (Engl); 1995 Oct; 108(10):760-3. PubMed ID: 8565662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical and pathological features of borderline ovarian tumors].
    Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
    Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
    Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors.
    Fu YS; Ro J; Reagan JW; Hall TL; Berek J
    Obstet Gynecol; 1986 Apr; 67(4):478-82. PubMed ID: 3960418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
    Lassus H; Staff S; Leminen A; Isola J; Butzow R
    Gynecol Oncol; 2011 Jan; 120(1):11-7. PubMed ID: 20937525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Morphometrical and immunohistochemical criteria of prognosis in patients with serous and mucinous ovarian carcinoma].
    Kolosov AE; Novichkov EV
    Arkh Patol; 2003; 65(5):29-32. PubMed ID: 14664145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of DNA content and nuclear morphology in borderline ovarian tumors.
    Drescher CW; Flint A; Hopkins MP; Roberts JA
    Gynecol Oncol; 1993 Feb; 48(2):242-6. PubMed ID: 8428698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphometry and digital AgNOR analysis in cytological imprints of benign, borderline and malignant serous ovarian tumours.
    Stemberger-Papić S; Stanković T; Vrdoljak-Mozetic D; Versa-Ostojić D; Krasević M; Stifter S; Audy-Jurković S
    Cytopathology; 2006 Dec; 17(6):382-9. PubMed ID: 17168922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computerized image analysis and flow cytometric evaluation of ovarian borderline tumors: a study of 24 cases.
    Esposito MJ; Fuchs A
    Cytometry; 1994 Dec; 18(4):218-22. PubMed ID: 7895528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
    Sun LX; Wu Y; Han HQ; Wang QH
    Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of genetic instability of nm23H1 gene to clinicopathologic features of epithelial ovarian carcinoma].
    Yang YQ; Li JC
    Ai Zheng; 2006 Jun; 25(6):713-7. PubMed ID: 16764766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis and prognosis of ovarian epithelial tumor with morphometry].
    Yin TJ; Gu MJ
    Ai Zheng; 2002 Jul; 21(7):781-4. PubMed ID: 12479107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
    Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P
    Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.